Menu

Blog

Jan 11, 2023

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

Posted by in categories: biotech/medical, robotics/AI

Even though the clinical efficacy of antibody-based therapeutics has been established, no methods that involve the de novo design of antibodies with wet lab validation are available.

About the study

A recent study, posted in the bioRxiv* preprint server, used generative AI models to develop de novo design antibodies against three distinct targets in a zero-shot fashion. A zero-shot designing method involves designing an antibody to bind to an antigen without follow-up optimization. The newly designed process has been termed de novo, meaning proteins (antibodies) were designed from first principles or from scratch.

Comments are closed.